Senior Therapeutic Area Specialist - Cardiovascular Community

Bristol Myers Squibb selects Houston for $2.3 billion manufacturing campus. Published. September 9, 2026 Bristol Myers Squibb has selected Houston for a new $2.3 billion manufacturing campus designed to produce multiple types of medicines and expand as the company's pipeline changes. The Generation Park site is expected to create nearly 500 permanent jobs. The approximately 600,000-square-foot campus will support small molecules, biologics, and antibody-drug conjugates, with manufacturing capabilities spanning late development through commercial launch. Its modular design will allow Bristol Myers Squibb to add or reconfigure capacity as product and pipeline needs evolve. The Houston project is part of the company's broader $40 billion commitment to U.S. research and development, technology, and domestic manufacturing over five years. Bristol Myers Squibb said the site will also incorporate digital systems and automation across its manufacturing operations. Construction is expected to create approximately 2,000 construction and indirect jobs between 2027 and 2030. Once operational, the campus is projected to employ nearly 500 people across production, engineering, maintenance, quality, and site operations. Bristol Myers Squibb selected Houston following an evaluation of multiple markets in the central and eastern United States. The company cited the region's life sciences workforce, infrastructure, available incentives, and access to transportation and utilities as factors in the decision.

Israel National Biotech Innovation Center (INBI) announces official launch and the appointment of Anat Cohen-Dayag, PhD, as Chief Executive Officer of INBI Core. Sep 08, 2026, 07:00 ET INBI is a transformational hub designed to unlock the value of Israel's world-class biomedical research and accelerate the development of breakthrough therapeutics Bringing together, for the first time, Israel's leading research institutions and medical centers to bridge the translational gap and create a pathway from groundbreaking science to new medicines Founding partners include Bar-Ilan University, Beilinson Hospital - Rabin Medical Center, Ben-Gurion University of the Negev, Clalit Health Services, Hadassah Medical Center, The Hebrew University of Jerusalem, Maccabi Healthcare Services, Rambam Health Care Campus, Shaare Zedek Medical Center, Sheba Medical Center, The Technion - Israel Institute of Technology, Tel Aviv Sourasky Medical Center (Ichilov), Tel Aviv University, The University of Haifa and the Weizmann Institute of Science TEL AVIV, Israel, Sept. 8, 2026 /PRNewswire/ - The Israel National Biotech Innovation Center (INBI) Ltd., designed to unlock Israel's world-class biomedical research for the development of new therapies, announced today the official launch of its activities. Anat Cohen-Dayag, PhD, Executive Chairperson of Compugen, has been appointed Chief Executive Officer of INBI Core Ltd., a wholly owned subsidiary of INBI. Samuel Moed, Former Head of Corporate Strategy at Bristol Myers Squibb, will serve as Chairperson of INBI and INBI Core. Founded in partnership with an unprecedented consortium of Israel's top academic and healthcare institutions, INBI brings together, for the first time, Israel's leading sources of life science innovation. Its founding partners include the following universities, research institutions and healthcare organizations (in alphabetical order): Bar-Ilan University, Beilinson Hospital - Rabin Medical Center, Ben-Gurion University of the Negev, Clalit Health Services, Hadassah Medical Center, The Hebrew University of Jerusalem, Maccabi Healthcare Services, Rambam Health Care Campus, Shaare Zedek Medical Center, Sheba Medical Center, The Technion - Israel Institute of Technology, Tel Aviv Sourasky Medical Center (Ichilov), Tel Aviv University, The University of Haifa and the Weizmann Institute of Science. INBI is a non-profit, national center of excellence with the mission of advancing Israel's disruptive academic research into breakthrough therapeutics. This bold, new model enables INBI to harness the breadth of Israel's world class research and benefit from a centralized translational engine designed to bridge the gap between academic discovery and clinical application. INBI was catalyzed under the umbrella of 8400 The Health Network, which continues to play a central role in advancing healthcare innovation as a key growth engine for the State of Israel. Powered by a network of global industry leaders, INBI will advance an exceptional portfolio of promising Israeli biomedical research programs. It will build a world-class team with deep expertise in early-stage drug development, provide the necessary infrastructure and funding and unlock capital and commercialization opportunities for the next generation of Israeli biotechs. "INBI represents a visionary model and marks the first-ever unity of all major sources of life sciences research in Israel, joining forces to create a national center of excellence with the mission of accelerating human cures," said Samuel Moed, Chairperson of INBI. "We are incredibly excited to have Anat, a top-tier biotech leader, head INBI Core. Anat brings three decades of experience in navigating the complex path from early-stage innovation to clinical-stage therapeutic development and vast experience in establishing partnerships with capital markets and strategics, making her the ideal leader to deliver on our mission. I also want to thank 8400 The Health Network, our amazing circle of Helix members and global advisors and Gornitzky GNY for their invaluable contribution to INBI." "Israel possesses world-class academic research, yet only a fraction of this potential successfully translates into scaled economic value and patient impact," said Dr. Cohen-Dayag. "Our model was created to fundamentally change this dynamic. By building a centralized translational engine we will supply the tools, infrastructure, knowledge, expertise, and capital needed to transform disruptive discoveries into potential global lifesaving therapies. I am looking forward to working with our distinguished founding partners and global key opinion leaders to drive this model." Inspired by biotech hubs around the world that have established above-institution centers of excellence, INBI adapts proven cross-institutional frameworks to the unique strengths of Israel's innovation ecosystem. Through INBI Core, the Center will operate a structured multi-year cohort lifecycle to de-risk projects, optimize leads, and prepare early-stage pipeline assets for robust commercial spinouts and investment. Dr. Anat Cohen-Dayag brings pioneering leadership, deep scientific expertise combined with extensive experience in the global biotechnology industry. Anat currently serves as Executive Chair of the Board of Compugen, following a distinguished career with the company spanning more than two decades, including 15 transformative years as President and Chief Executive Officer. Under her executive direction, Compugen evolved from a computational biology service provider into a clinical-stage therapeutic developer specializing in cancer immunotherapy, successfully forging major international pharma partnerships. She holds an MS in Chemical Immunology and a PhD in Cellular Biology from the Weizmann Institute of Science, combining rigorous scientific credentials with a proven track record of driving corporate strategy, global operations, strategic partnering, financing and the translation of innovative discovery into clinical-stage assets. Samuel Moed is an accomplished healthcare executive with over three decades of leadership experience in global biopharmaceuticals and health technology. He spent a distinguished career at Bristol Myers Squibb (BMS), where he ultimately served as Senior Vice President of Corporate Strategy. Today, Mr. Moed is focused on helping Israel realize the full potential of its life science innovation and elevating Israel's impact and reputation in the global healthcare market. About INBI and INBI Core The Israel National Biotech Innovation Center (INBI) Ltd. is a non-profit national platform that brings together projects from Israel's world-class universities, research hospitals and healthcare organizations under one umbrella to create a powerful engine of innovation. INBI Core Ltd., a wholly owned subsidiary of INBI, is a centralized operational hub, designed to bridge the gap between academic discovery and clinical application. It will provide the infrastructure, knowledge, talents, and capital to advance the development of breakthrough therapeutics and unlock opportunities for robust commercial spinouts and investment. Media contact: Tsipi Haitovsky Global Media Liaison The Israel National Biotech Innovation Center [email protected] SOURCE Israel National Biotech Innovation Center

Daily health news issue # 590 for 9/5/2026. Human-in-the-Loop Notes (see table further below for links and summaries): * An editorial in the NY Times critiques the increasing hassles to set/up and conduct Phase 1 trials - with the result that pharma companies are looking overseas to do trials. * 80% of patients who appeal prior authorization denials succeed in overturning the denial. * Success relies on persistence, precise documentation of diagnosis, and providing current clinical research to counter outdated insurer policies. * Mistrial declared in the Lindsay Clancy trial. * The reason FHIR-Engine is following this - is that the case (if ever brought to successful trial) has huge implications for precedence: can post partum psychosis be a defense in horrific child cases. * The Tempus AI story is about a growing market for companies that can help biotech firms to identify tumor DNA. * Driven in large part by the growing success of folks like Moderna to come up with mRNA therapies for pancreatic cancer. * Looks like alcoholic-related cancer deaths have doubled in the USA since 1990. * Researchers found that even one standard drink daily increases the risk of mortality from several cancers, including breast, colorectal, liver, and head and neck cancers. * And again - best advice seems to be to rarely drink. * Sucks. On that note - have good weekend. See its "top articles" list below. For a synoposis of all 45 articles curated today, see further below, and to see each of these articles listed with short summary just click here. Audio/Video. "They're our own bodies. We're more familiar, you know, so we're more likely to recognize something unusual,"... - Gloria Steinem (commenting on American Cancer Society recommendations related to self-examination) | Article_Title | Article_Takeaway | | How to Train Balance as You Age | Balance naturally declines with age, but can be restored and maintained through targeted strength training, flexibility exercises, and activities that challenge sensory and cognitive systems. | | The Search for New Cures Is Broken | Excessive regulatory burdens and rising costs are slowing U.S. clinical trials, forcing researchers abroad and hindering the development of life-saving medical breakthroughs. | | Drugmakers Halt Autoimmune Trials After Deaths, Life-Threatening Side Effects | Novartis and Bristol Myers have paused clinical trials for experimental autoimmune CAR-T therapies following reports of patient deaths and life-threatening side effects, raising concerns about transparency in drug research. | | The muscle ability you lose fastest with age - and how to preserve it | Muscular power, the ability to produce force quickly, declines faster than strength with age, but can be improved at any age through specialized resistance training. | | Just one drink a day may increase the risk of dying from numerous cancers | A new study indicates that even one standard alcoholic drink daily can increase the risk of dying from various cancers, with alcohol-attributable cancer deaths in the US more than doubling over three decades. | | How to Appeal Your Health Insurer's 'Prior Authorization' Denial - and Win | While many patients give up after a prior-authorization denial, appealing with medical evidence and persistence is often successful. | | The Cancer Vaccine Gold Rush Has Begun. So Has the Race for Picks and Shovels. Tempus AI's acquisition of Personalis positions the diagnostic company to play a key role in the burgeoning personalized mRNA cancer vaccine market. | | Lindsay Clancy Murder Trial Ends in Mistrial | A Massachusetts jury failed to reach a verdict in the trial of Lindsay Clancy, who pleaded not guilty by reason of insanity for the murder of her three children while allegedly suffering from postpartum psychosis. | Today's graphic. 8.13.26-Youth-AI-Mental-Health-Advice-NIHCM-Foundation-August-2026 (Source:). See below or click here Today's digest. Here is a summary of all 45 articles curated today into the Competitive Research Analytics Platform for 9/5/2026: Here is a summary of all the articles curated into the Competitive Research Analytics Platform for September 5, 2026: Healthcare policy and operational challenges dominate recent developments across Medicare, Medicaid, and commercial insurance markets. The Medicare Shared Savings Program continues supporting ACO participation through updated CMS guidance, while remote patient monitoring faces significant threats from proposed payment reductions despite over 200 stakeholder objections. Multiple states are implementing work requirements for Medicaid beneficiaries, with Oklahoma warning that 250,000 SoonerCare members and North Carolina launching educational toolkits to prepare affected populations. Disabled workers face particular vulnerability given their reliance on public insurance amid tightening eligibility rules. Clinical and technological innovations are reshaping care delivery. UnitPoint Health achieved zero maternal sepsis mortality through integrated Epic EHR algorithms, while Iowa health systems streamlined organ donor registration via MyChart portals. AI scribes reduce physician documentation burden, and Hospital at Home programs are scaling following extended federal reimbursement. North Carolina renewed its peer mental health support program for teens after demonstrating measurable reductions in suicidal ideation through 2.1 million messages. However, innovation faces headwinds: drugmakers halted autoimmune CAR-T trials following patient deaths, and the FDA recalled Boston Scientific spinal cord stimulator leads, raising transparency concerns. Insurance and workforce dynamics reveal market consolidation and geographic shifts. Hospital mergers are accelerating after a 2025 slowdown, while physicians migrate from saturated Northeast markets to growing Southern and Western regions offering lower costs and higher demand. Medicare Advantage satisfaction declined for the second year as insurers narrow networks and cut benefits to rebuild margins. Medicaid reimbursement rates for preventive care lag significantly behind other insurance types in Virginia. Compliance challenges persist, including tobacco surcharge wellness program guidance and $1.6 million Medicaid fraud prosecution, while states must strategically deploy AI in redeterminations to avoid wrongful disenrollment. Federal investments totaling $106.48 million target rural healthcare workforce development and technology modernization across Rhode Island, Michigan, and New York. As of today, C.R.A.P. now has 229 subscribers. Want to drop FHIR-Engine a line? E-Mail Us